An efficient and selective microwave-assisted Claisen-Schmidt reaction for the synthesis of functionalized benzalacetones

Molecular Engineering of Highly Fluorinated Carbon Dots: Tailoring Li+ Dynamics and Interfacial Fluorination for Stable Solid Lithium Batteries

Fluorinated carbon dots (FCDs) have garnered interest owing to their distinct physicochemical properties. Nevertheless, intricate synthesis procedures and quite low fluorine doping levels limit its development and application. Herein, we propose a facile approach based on the Claisen-Schmidt reaction to realize gram-scale synthesis of highly fluorinated carbon dots (up to 20.79 at. %) at room temperature and atmospheric pressure, and a comprehensive exploration of the specific reaction mechanism is conducted. Furthermore, in consideration of the high fluorine content, good dispersibility, and compatibility with polymer electrolyte, the synthesized FCDs are utilized as an additive for PEO-based solid electrolytes of a Li battery to improve its ionic conductivity, interface stability, and mechanical properties. The introduction of FCDs can not only reduce the crystallinity of PEO and enhance the interaction of polymer chains, but also facilitate the establishment of uninterrupted pathways and in situ fluorination at the interface, which is substantiated by both theoretical calculations and experimental findings. As a result, the lithium symmetrical battery can operate stably for 1000 h at a current density of 0.4 mA cm-2. Simultaneously, the LiFePO4/Li battery utilizing the composite electrolyte exhibits a capacity of 130.3 mAh g-1 over 300 cycles while maintaining a capacity retention rate of 95.10%. This study develops a strategy for synthesizing highly fluorinated carbon dots, which demonstrate a useful influence on PEO electrolytes, thus boosting the advancement of FCDs and solid-state batteries.

Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers

Due to hurdles, including resistance, adverse effects, and poor bioavailability, among others linked with existing therapies, there is an urgent unmet need to devise new, safe, and more effective treatment modalities for skin cancers. Herein, a series of flavonol-based derivatives of fisetin, a plant-based flavonoid identified as an anti-tumorigenic agent targeting the mammalian targets of rapamycin (mTOR)-regulated pathways, were synthesized and fully characterized. New potential inhibitors of receptor tyrosine kinases (c-KITs), cyclin-dependent kinase-2 (CDK2), and mTOR, representing attractive therapeutic targets for melanoma and non-melanoma skin cancers (NMSCs) treatment, were identified using inverse-docking, in vitro kinase activity and various cell-based anticancer screening assays. Eleven compounds exhibited significant inhibitory activities greater than the parent molecule against four human skin cancer cell lines, including melanoma (A375 and SK-Mel-28) and NMSCs (A431 and UWBCC1), with IC50 values ranging from 0.12 to < 15 μM. Seven compounds were identified as potentially potent single, dual or multi-kinase c-KITs, CDK2, and mTOR kinase inhibitors after inverse-docking and screening against twelve known cancer targets, followed by kinase activity profiling. Moreover, the potent compound F20, and the multi-kinase F9 and F17 targeted compounds, markedly decreased scratch wound closure, colony formation, and heightened expression levels of key cancer-promoting pathway molecular targets c-Kit, CDK2, and mTOR. In addition, these compounds downregulated Bcl-2 levels and upregulated Bax and cleaved caspase-3/7/8 and PARP levels, thus inducing apoptosis of A375 and A431 cells in a dose-dependent manner. Overall, compounds F20, F9 and F17, were identified as promising c-Kit, CDK2 and mTOR inhibitors, worthy of further investigation as therapeutics, or as adjuvants to standard therapies for the control of melanoma and NMSCs.

A bioinspired microreactor with interfacial regulation for maximizing selectivity in a catalytic reaction

We report a bioinspired emulsion microreactor composed of an electrical double layer to mimic the functions of cell membranes. This "artificial cell" can modulate the phase-oriented transport of reagents at the oil-liquid interface via the electrical double layer, affording a powerful tool to optimize the selectivity in a catalytic reaction.

Evaluation of sulphonamide derivatives acting as inhibitors of human carbonic anhydrase isoforms I, II and Mycobacterium tuberculosis β-class enzyme Rv3273

A series of novel sulphonamide derivatives was obtained from sulphanilamide which was N4-alkylated with ethyl bromoacetate followed by reaction with hydrazine hydrate. The hydrazide obtained was further reacted with various aromatic aldehydes. The novel sulphonamides were characterised by infrared, mass spectrometry, 1H- and 13C-NMR and purity was determined by high-performance liquid chromatography (HPLC). Human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms hCA I and II and Mycobacterium tuberculosis β-CA encoded by the gene Rv3273 (mtCA 3) inhibition activity was investigated with the synthesised compounds which showed promising inhibition. The KIs were in the range of 54.6 nM-1.8 µM against hCA I, in the range of 32.1 nM-5.5 µM against hCA II and of 127 nM-2.12 µM against mtCA 3.

New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling

In this work, a serie of cyclocoumarol derivatives was designed, synthesized, characterized and studied for their potentialities as selective inhibitors of COX-2. All target compounds have been screened for their anti-inflammatory activity by the assay of PGE₂ production. Among them, compound 5d exhibited the most potent inhibitory activity with a PGE₂ inhibition compared to NS-398 (79% and 88% respectively) and showed non-inhibitory activity towards the COX-1 enzyme. Docking studies revealed the capacity of this compound to occupy the selective COX-2 cavity establishing additional hydrogen bonds between the oxygen of the methoxy group and the His90 and Arg513 of the binding site of the enzyme.